Anaxis Pharma: Ledger

Investor	Rounds	Invested
MTPConnect	Accelerator · Grant	-

Company	Kind	Announced	Price	Sources
Anaxis Pharma is not recorded as having acquired anything.

Coverage

Stories naming Anaxis Pharma. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

14 deals

Life sciences investor MTPConnect injects $12 million into 14 drug and device startups

MTPConnect's government-backed accelerator program has awarded $12.07 million in non-dilutive grants to 14 Australian drug and device companies, which will also receive mentoring and support from partners including CSL and Roche Diagnostics.

Startup Daily 23 Jun 2025 Anaxis Pharma Argenica Therapeutics Aspecthera Atherid Therapeutics CathRx Ltd Endo Axiom I D & E Inosi Therapeutics Nanomedx ProGenis Pharmaceuticals Theia Medical Venstra Medical Wavewise Analytics ZiP Diagnostics CSL Medical Research Future Fund MTPConnect Stuart Dignam

Also SmartCompany·@AuManufacturing

Funding announcement

Professor got nothing from the $2.8b sale of his molecule, and that's okay

Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.

Fund close $20m

Scientist behind Australia’s highest-priced molecule reveals how to profit from early stage biotechs

Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.

Synthesis BioVentures 5 Sep 2023 SYNthesis BioVentures Aculeus Therapeutics Pty Ltd Anaxis Pharma GSK Merck Pfizer Servier SYNthesis Group SYNthesis Med Chem Amir Zalcenstein Prof Andrew Wilks

Anaxis Pharma

Funding history

Investors

What Anaxis Pharma bought

People

Coverage

Life sciences investor MTPConnect injects $12 million into 14 drug and device startups

Professor got nothing from the $2.8b sale of his molecule, and that's okay

Scientist behind Australia’s highest-priced molecule reveals how to profit from early stage biotechs